Association of the CYP19A1 rs700518 Polymorphism with Selected Markers of Bone Metabolism in Women with Hyperandrogenism

• Published in: Journal of clinical medicine Vol. 11; no. 12; p. 3537
• Main Authors: Uzar, Izabela, Bogacz, Anna, Sowińska-Przepiera, Elżbieta, Piątek, Krzysztof, Przerwa, Filip, Wolek, Marlena, Czerny, Bogusław
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 20.06.2022; MDPI
• Subjects: Amenorrhea; Androgens; Body fat; Bone density; Clinical medicine; Congenital diseases; Endocrinology; Enzymes; Estrogens; Genotype & phenotype; Hyperplasia; Hypothalamus; Immunoassay; Laboratories; Metabolic disorders; Mineralization; Osteoporosis; Ovaries; Polycystic ovary syndrome; Polymorphism; Puberty; Testosterone; Variance analysis; United States > US
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11123537

Hyperandrogenism is the most common endocrine disorder in women, characterized by an imbalance of normal estrogen and androgen levels in the blood. Androgens play an important role in the female body because they influence bone mineral density (BMD), body mass composition, muscle mass, mental state, and the regulation of sexual function. The reduced activity of aromatase, due to mutations in the CYP19A1 gene, reduces the estrogen pool in favor of androgens. Clinically, aromatase deficiency causes hyperandrogenism in women. Therefore, the aim of the study was to assess the effect of the CYP19A1 gene polymorphism on selected markers of bone metabolism and hormonal parameters in women with hyperandrogenism. The study group was comprised of 80 young women with hyperandrogenism who underwent measurements of bone mineral density (BMD), and determination of hormonal and metabolic parameters. Enzyme immunoassays were used to measure leptin, total sRANKL (free and bound RANKL), osteoprotegerin, and total 25-OH Vitamin D. An analysis of the CYP19A1 gene polymorphisms was performed using the real-time PCR method. The GG genotype of the CYP19A1 rs700518 polymorphism turned out to be associated with: FEI (Free Estradiol Index), SHGB concentration, estradiol concentration, and insulin concentration determined in the glucose tolerance test 60’ compared to AG and AA genotypes. Patients with the AG genotype had a higher ratio of android to gynoid fat and a greater content of visceral adipose tissue. Higher visceral tissue content may reduce BMD. In conclusion, the study showed that the CYP19A1 rs700518 polymorphism may be associated with the distribution of adipose tissue in young women with hyperandrogenism. These results suggest that patients with the AG genotype may develop osteoporosis.